Editor´s Pick

Editor´s Pick

Moderna Announces First Participant Dosed in Phase 2/3 Study of its mRNA Respiratory Syncytial Virus (RSV) Vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first participant has been dosed...

Admin - November 18, 2021

Editor´s Pick

Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced it is seeking Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, PAXLOVID™ (PF-07321332; ritonavir), for the...

Admin - November 16, 2021

Editor´s Pick

Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries

NEW YORK & GENEVA--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and the Medicines Patent Pool (MPP), a United Nations-backed public health organization working to increase access...

Admin - November 16, 2021

Editor´s Pick

Amcyte Pharma Announces U.S. Launch of Nasitrol® Nasal Spray

KIRKLAND, Wash.--(BUSINESS WIRE)--Amcyte Pharma, a Seattle-based company dedicated to the development of novel pharmaceutical products in immunology, announced the U.S. launch of its Nasitrol®...

Admin - November 16, 2021

Editor´s Pick

Moderna Announces European Union and European Economic Area Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to COVAX in 2021...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement that enables the European...

Admin - November 16, 2021

Editor´s Pick

epocrates Builds the Future of Digital Continuing Medical Education with Optimized In-App Interface and New Conveniences for Busy Clinicians

WATERTOWN, Mass.--(BUSINESS WIRE)--epocrates, an athenahealth, Inc., company that delivers digital clinical decision support to prescribers, today announced it has released the latest version of...

Admin - November 16, 2021

123...10 Page 2 of 10

Recent Articles

Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate...

QIAGEN reaffirms effectiveness of its SARS-CoV-2 PCR tests in light of the new coronavirus variant B.1.1.529

Enzychem to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea

Impetus Digital wins Canada’s Most Admired Corporate Cultures Awards 2021

VARIANT Receives European Orphan Drug Designation for its Gene Therapy Product Candidate, VAR002, for the Treatment of Both Leber Congenital Amaurosis and Cone-Rod dystrophy

Trodelvy® (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line

Donaldson Company Acquires Solaris Biotechnology

Troy Hilsenroth Appointed CEO of biolog-id

MyMD Pharmaceuticals Announces Issuance of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending Lifespan

IncellDx Awarded Patent for Use of CCR5 Antagonist Maraviroc in Treatment of COVID-19

Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib)

Donaldson Company acquisisce Solaris Biotechnology

Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML

Takeda’s LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory...

Donaldson Company adquiere Solaris Biotechnology